<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871321</url>
  </required_header>
  <id_info>
    <org_study_id>2021-03-045</org_study_id>
    <nct_id>NCT04871321</nct_id>
  </id_info>
  <brief_title>Biomarker Discovery in Patients With Advanced Biliary Tract Cancer</brief_title>
  <official_title>Discovery of Molecular Biomarkers for Predicting Response Through RNA Sequencing in Patients With Advanced Biliary Tract Cancer Who Received Nab-paclitaxel Plus Gemcitabine-cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHA University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dong-A Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CHA University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biliary tract cancer is a rare gastrointestinal malignant neoplasm and includes intrahepatic&#xD;
      cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gall bladder cancer. Curative&#xD;
      surgical resection offers the only chance for cure. However, most patients with BTC are&#xD;
      diagnosed at an unresectable stage. Therefore, the survival outcomes of patients with&#xD;
      advanced biliary tract cancer remain dismal.&#xD;
&#xD;
      The combination of gemcitabine and cisplatin has become the current standard for advanced&#xD;
      BTCs since the landmark ABC-02 trial in 2010. However, the median overall survival of Gem/Cis&#xD;
      chemotherapy is less than 1 year. Recently, a triplet regimen of gemcitabine, cisplatin, and&#xD;
      nab-paclitaxel showed promising results in a single-arm phase II multicenter study.&#xD;
&#xD;
      However, biliary tract cancer is a group of heterogenous diseases by site and genetic&#xD;
      alteration, and this diversity may lead differences in response to systemic chemotherapy.&#xD;
&#xD;
      Transcriptome analysis through RNA-sequencing has rarely been performed in advanced biliary&#xD;
      tract cancer, and even if it has performed, only small number of patients were included.&#xD;
      Further research on multi-omics data is needed on the necessity and clinical significance in&#xD;
      treatment of biliary tract cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using biopsy specimen (formalin fixed paraffin embedded tissue), in-house NGS and&#xD;
      RNA-sequencing will be performed simultaneously. Through this, investigators will discover&#xD;
      biomarkers based on multi-omics data that predict response to systemic chemotherapy&#xD;
      (nab-paclitaxel plus gemcitabine-cisplatin). In addition, blood sampling will be performed in&#xD;
      parallel to conduct research on cell-free DNA and circulating tumor cell analysis related to&#xD;
      response and progression on chemotherapy; before administration of chemotherapy, 3 months&#xD;
      after chemotherapy, 6 months after chemotherapy, the time of disease progression (if&#xD;
      possible), before curative resection (if possible).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>collected tumor samples</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>tumor samples from patients with hepatobiliary cancers (incidence of genetic alteration, association with treatment response and survival duration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>collected blood samples</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>blood samples from patients with hepatobiliary cancers (incidence of genetic alteration, association with treatment response and survival duration)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multi-omics analysis</measure>
    <time_frame>2 years</time_frame>
    <description>Multi-omics analysis to further subtype and find therapeutic targets of biliary tract cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers on the efficacy of Gemcitabine/Cisplatin/Nab-paclitaxel for advanced biliary tract cancer</measure>
    <time_frame>2 years</time_frame>
    <description>Molecular biomarker associated with overall survival, progression-free survival and objective response rate in patients who receive Gemcitabine/Cisplatin/Nab-paclitaxel chemotherapy</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Gallbladder Cancer</condition>
  <arm_group>
    <arm_group_label>Gem/Cis/nab-P</arm_group_label>
    <description>Gemcitabine + Cisplatin + Nab-Paciltaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel plus gemcitabine-cisplatin</intervention_name>
    <description>- gemcitabine 800mg/m2 + cisplatin 25 mg/m2 + nab-paclitaxel 100mg/m2 on day 1 and day 8, every 21 days</description>
    <arm_group_label>Gem/Cis/nab-P</arm_group_label>
    <other_name>immunohistochemistry, NGS, RNA-sequencing, Liquid biopsy</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue, Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced biliary tract cancer will be recruited at CHA Bundang Medical Center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 19 years old&#xD;
&#xD;
          -  Capable of understanding and complying with the protocol requirements and signed&#xD;
             informed consent&#xD;
&#xD;
          -  The patients were confirmed as bilary tract cancer (gall bladder cancer, extrahepatic&#xD;
             cholangiocarcinoma, intrahepatic cholangiocarcinoma) by histopathology or cytology&#xD;
&#xD;
          -  Patients with inoperable or metastatic or recurrent biliary tract cancer&#xD;
&#xD;
          -  Patients who underwent in-house next-generation sequencing&#xD;
&#xD;
          -  Patients planning to receive Gemcitabine, Cisplatin, nab-paclitaxel triplet&#xD;
             chemotherapy&#xD;
&#xD;
          -  At least one measurable objective lesion was identified based on the RECIST 1.1&#xD;
             criteria&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
&#xD;
          -  The expected survival a ≥3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has uncontrolled, significant intercurrent or recent illness including&#xD;
             infection for organ failure&#xD;
&#xD;
          -  Prior palliative chemotherapy for biliary tract cancer&#xD;
&#xD;
          -  Dementia, altered mental state, or any mental illness that prevents understanding or&#xD;
             informed consent&#xD;
&#xD;
          -  Other conditions that researchers not think to be suitable for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongjae Chon, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong Jae Chon, MD,PhD</last_name>
    <phone>82-31-780-3928</phone>
    <email>minidoctor@cha.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHA Bundang Medical Center</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Jae Chon, MD, PhD</last_name>
      <phone>82-31-780-3928</phone>
      <email>minidoctor@cha.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.274</url>
    <description>Efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin (GemCis/nab-P) in Korean patients with advanced biliary tract cancers (aBTC): Multicenter retrospective analysis.</description>
  </link>
  <reference>
    <citation>Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BS J, Youssef BA M, Klimstra D, Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9.</citation>
    <PMID>11573044</PMID>
  </reference>
  <reference>
    <citation>Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.</citation>
    <PMID>20375404</PMID>
  </reference>
  <reference>
    <citation>Kim BJ, Hyung J, Yoo C, Kim KP, Park SJ, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Park JH, Cho H, Ryoo BY, Chang HM. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemother Pharmacol. 2017 Jul;80(1):209-215. doi: 10.1007/s00280-017-3353-2. Epub 2017 Jun 8.</citation>
    <PMID>28597043</PMID>
  </reference>
  <reference>
    <citation>Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jun 1;5(6):824-830. doi: 10.1001/jamaoncol.2019.0270.</citation>
    <PMID>30998813</PMID>
  </reference>
  <reference>
    <citation>Chae H, Kim D, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Hwang S, Kim KH, Song GW, Ahn CS, Lee JH, Hwang DW, Kim SC, Jang SJ, Hong SM, Kim TW, Ryoo BY. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker. Eur J Cancer. 2019 Oct;120:31-39. doi: 10.1016/j.ejca.2019.07.022. Epub 2019 Aug 30.</citation>
    <PMID>31476489</PMID>
  </reference>
  <reference>
    <citation>Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, Hama N, Hosoda F, Urushidate T, Ohashi S, Hiraoka N, Ojima H, Shimada K, Okusaka T, Kosuge T, Miyagawa S, Shibata T. Genomic spectra of biliary tract cancer. Nat Genet. 2015 Sep;47(9):1003-10. doi: 10.1038/ng.3375. Epub 2015 Aug 10.</citation>
    <PMID>26258846</PMID>
  </reference>
  <reference>
    <citation>Chu KJ, Ma YS, Jiang XH, Wu TM, Wu ZJ, Li ZZ, Wang JH, Gao QX, Yi B, Shi Y, Wang HM, Gu LP, Zhang SQ, Wang GR, Liu JB, Fu D, Jiang XQ. Whole-Transcriptome Sequencing Identifies Key Differentially Expressed mRNAs, miRNAs, lncRNAs, and circRNAs Associated with CHOL. Mol Ther Nucleic Acids. 2020 Sep 4;21:592-603. doi: 10.1016/j.omtn.2020.06.025. Epub 2020 Jun 27.</citation>
    <PMID>32721879</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biliary Tract cancer</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>nab-paclitaxel</keyword>
  <keyword>RNA sequencing</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

